Pharmacological Correction of Neurological Disorders in Case of Multiple Sclerosis

The article analyzes the possibility of drug correction of common neurological disorders (pain, anxiety, depression, insomnia) using antidepressants under the conditions of experimental equivalent of multiple sclerosis on the background of basic drug therapy with methylprednisolone. Assessment of antidepressants antinociceptive potential identified “a range of activity” of the mentioned medicines (analgesic activity of classical amitriptyline antidepressant was accepted as conventional unit): paroxetine (0.9 c.u.), amitriptyline (1 c.u.), fluoxetine (1.11 c.u.) and trittico (1.16 c.u.). Comparative analysis of the duration of animals’ fading in the water at the forced swimming (Porsolt forced swimming test) found that the ability to weaken the level of anxiety and concern was the most significant for trittico and paroxetine groups. Immobilization time was 1.7 (p£0.05) and 1.6 (p£0.05), respectively, which was shorter than the corresponding figures of the active control group. The effect of antidepressants on latency, sleep duration when administered on a background of basic drug therapy with methylprednisolone was characterized by the following indicators: trittico (-66.5% and + 133.45%)?fluoxetine (-60.5% and + 117.79%)?paroxetine (-61.8% and + 93.59%)?amitriptyline (-52.75% and + 81.85%). Thus, trittico and paroxetine were reasonable to administer under the experimental equivalent of multiple sclerosis taking into account the basic hormonal therapy as a means of drug correction of pain, anxiety, depression and sleep disorders.